A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis

References

• Fermand JP, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(1478–1485):1478–1485.
   PubMedGoogle Scholar
• Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520–2530.
   PubMed Web of Science ®Google Scholar
• Merlini G, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.
   PubMed Web of Science ®Google Scholar
• Nuvolone M, Milani P, Palladini G, et al. Management of the elderly patient with AL amyloidosis. Eur J Intern Med. 2018;58:48–56.
   PubMed Web of Science ®Google Scholar
• Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492–1495.
   PubMed Web of Science ®Google Scholar
• Palladini G, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(2325–2332):2325–2332.
   Google Scholar
• Kourelis TV, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31(34):4319–4324.
   PubMed Web of Science ®Google Scholar
• Sachchithanantham S, et al. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. J Clin Oncol. 2016;34(17):2037–2045.
   PubMed Web of Science ®Google Scholar
• Basset M, et al. Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. Blood. 2020;135(4):293–296.
   PubMed Web of Science ®Google Scholar
• Nevone A, Merlini G, Nuvolone M. Treating Protein Misfolding Diseases: therapeutic Successes Against Systemic Amyloidoses. Front Pharmacol. 2020;11:1024.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Kyle RA, Greipp PR. The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood. 1989;74(3):1108–1111.
   PubMed Web of Science ®Google Scholar
• Sidiqi MH, et al. Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica. 2018;103(7):1229–1234.
   PubMed Web of Science ®Google Scholar
• Jones NF, Hilton PJ, Tighe JR, et al. Treatment of “primary” renal amyloidosis with melphalan. Lancet. 1972;2(7778):616–619.
   PubMed Web of Science ®Google Scholar
• Sidana S, et al. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. Am J Hematol. 2019;94(9):1020–1026.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015;126(20):2345–2347.
   PubMed Web of Science ®Google Scholar
• Muchtar E, et al. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol. 2019;187(5):588–594.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant. 2013;48(10):1302–1307.
   PubMed Web of Science ®Google Scholar
• D’Souza A, et al. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: a Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015;33(32):3741–3749.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Hematol Oncol Clin North Am. 2014;28(6):1131–1144.
   PubMed Web of Science ®Google Scholar
• Skinner M, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140(2):85–93.
   PubMed Web of Science ®Google Scholar
• Jaccard A, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083–1093.
   PubMed Web of Science ®Google Scholar
• Gertz MA, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51(12):2181–2187.
   PubMed Web of Science ®Google Scholar
• Sidiqi MH, et al. Stem Cell Transplantation for Light Chain Amyloidosis: decreased Early Mortality Over Time. J Clin Oncol. 2018;36(13):1323–1329.
   PubMed Web of Science ®Google Scholar
• Gertz MA, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011;46(7):970–975.
   PubMed Web of Science ®Google Scholar
• Sharpley FA, et al. A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. Br J Haematol. 2019;187(5):642–652.
   PubMed Web of Science ®Google Scholar
• Gertz MA, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557–561.
   PubMed Web of Science ®Google Scholar
• Sidiqi MH, et al. Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. Bone Marrow Transplant. 2019;54(11):1775–1779.
   PubMed Web of Science ®Google Scholar
• Leung N, Kumar SK, Glavey SV, et al. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology Dialysis Transplantation. 2016;31(8):1284–1289.
   PubMed Web of Science ®Google Scholar
• Batalini F, et al. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Biol Blood Marrow Transplant. 2018;24(1):127–132.
   PubMed Web of Science ®Google Scholar
• Sidiqi MH, et al. Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biol Blood Marrow Transplant. 2018;24(10):2157–2159.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol. 1999;104(3):553–559.
   PubMed Web of Science ®Google Scholar
• Gertz MA, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant. 2004;34(12):1025–1031.
   PubMed Web of Science ®Google Scholar
• Cibeira MT, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118(16):4346–4352.
   PubMed Web of Science ®Google Scholar
• Tandon N, et al. Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. Bone Marrow Transplant. 2017;52(8):1126–1132
   PubMed Web of Science ®Google Scholar
• Hwa YL, et al. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. Am J Hematol. 2016;91(10):984–988.
   PubMed Web of Science ®Google Scholar
• Manwani R, et al. Deferred autologous stem cell transplantation in systemic AL amyloidosis. Blood Cancer J. 2018;8(11):101.
   PubMedGoogle Scholar
• Basset M, et al. Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. Blood Adv. 2020;4(17):4175–4179.
   PubMed Web of Science ®Google Scholar
• Palladini G, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936–2938.
   PubMed Web of Science ®Google Scholar
• Palladini G, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014;99(4):743–750.
   PubMed Web of Science ®Google Scholar
• Kastritis E, et al. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. J Clin Oncol. 2020;38(28):3252–3260.
   PubMed Web of Science ®Google Scholar
• Gertz MA, et al. Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica. 2008;93(9):1402–1406.
   PubMed Web of Science ®Google Scholar
• Lentzsch S, et al. Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: results of a Phase II Study. J Clin Oncol. 2020;38(13):1455–1462.
   PubMed Web of Science ®Google Scholar
• Milani P, et al. Treatment of AL amyloidosis with bendamustine: a study of 122 patients. Blood. 2018;132(18):1988–1991.
   PubMed Web of Science ®Google Scholar
• Chauhan D, et al. In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells. Clin Cancer Res off J Am Assoc Cancer Res. 2013;19(11):3019–3031.
   PubMed Web of Science ®Google Scholar
• Wickstrom M, et al. Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017;8(39):66641–66655.
   PubMedGoogle Scholar
• Richardson PG, et al. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study. Lancet Haematol. 2020;7(5):e395–e407.
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nature Reviews Cancer. 2004;4(5):349–360.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy.. Clin Cancer Res. 1999;5(9):2638–2645.
   PubMed Web of Science ®Google Scholar
• Broyl A, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010;11(11):1057–1065.
   PubMed Web of Science ®Google Scholar
• Kastritis E, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031–1037.
   PubMed Web of Science ®Google Scholar
• Reece DE, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865–873.
   PubMed Web of Science ®Google Scholar
• Oliva L, et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood. 2017;129(15):2132–2142.
   PubMed Web of Science ®Google Scholar
• Reeder CB, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115(16):3416–3417.
   PubMed Web of Science ®Google Scholar
• Moreau P, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440.
   PubMed Web of Science ®Google Scholar
• Kastritis E et al. Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed light chain (AL) amyloidosis: primary results from the phase 3 ANDROMEDA Study EHA25 Abstract LB2604 2020
   Google Scholar
• Palladini G, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–615.
   PubMed Web of Science ®Google Scholar
• Kastritis E, et al. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015;90(4):E60–65.
   PubMed Web of Science ®Google Scholar
• Shah C, et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma. 2018;59(11):2557–2569.
   PubMed Web of Science ®Google Scholar
• Manwani R, et al. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. Br J Haematol. 2019;187(5):638–641.
   PubMed Web of Science ®Google Scholar
• Kupperman E, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70(5):1970–1980.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597–605. Blood 135, 1071, doi: 10.1182/blood-2017-03-771220( 2020.
   PubMed Web of Science ®Google Scholar
• Cohen OC, et al. Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. Br J Haematol. 2020;189(4):643–649
   PubMed Web of Science ®Google Scholar
• Quach H, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22–32.
   PubMed Web of Science ®Google Scholar
• Ito T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345–1350.
   PubMed Web of Science ®Google Scholar
• Ito T, Handa H. Molecular mechanisms of thalidomide and its derivatives. Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(6):189–203.
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699–703.
   PubMed Web of Science ®Google Scholar
• Singhal S, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–1571.
   PubMed Web of Science ®Google Scholar
• Palumbo A, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968–3977.
   PubMed Web of Science ®Google Scholar
• Seldin DC, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma. 2003;3(4):241–246.
   PubMedGoogle Scholar
• Dispenzieri A, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003;10(4):257–261.
   PubMed Web of Science ®Google Scholar
• Palladini G, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL. Blood. 2005;105(7):2949–2951.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457–464.
   PubMed Web of Science ®Google Scholar
• Palladini G, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol. 2009;88(4):347–350.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465–470.
   PubMed Web of Science ®Google Scholar
• Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079–2080.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492–496.
   PubMed Web of Science ®Google Scholar
• Specter R, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dialysis Trans. 2011;26(3):881–886.
   PubMed Web of Science ®Google Scholar
• Moreau P, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010;116(23):4777–4782.
   PubMed Web of Science ®Google Scholar
• Dinner S, et al. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica. 2013;98(10):1593–1599.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, et al. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013;98(5):789–792.
   PubMed Web of Science ®Google Scholar
• Hegenbart U, et al. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica. 2017;102(8):1424–1431.
   PubMed Web of Science ®Google Scholar
• Palladini G, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica. 2013;98(3):433–436.
   PubMed Web of Science ®Google Scholar
• Kastritis E, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012;119(23):5384–5390.
   PubMed Web of Science ®Google Scholar
• Kumar SK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119(21):4860–4867.
   PubMed Web of Science ®Google Scholar
• Cibeira MT, et al. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br J Haematol. 2015;170(804–813):804–813.
   PubMedGoogle Scholar
• Sanchorawala V, et al. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128(8):1059–1062.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012;119(23):5397–5404.
   PubMed Web of Science ®Google Scholar
• Palladini G, et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017;129(15):2120–2123.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020;135(18):1541–1547.
   PubMed Web of Science ®Google Scholar
• Roussel M, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020;135(18):1531–1540.
   PubMed Web of Science ®Google Scholar
• Kumar S, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401–2409.
   PubMed Web of Science ®Google Scholar
• Kumar S, et al. Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. J Clin Oncol. 2020;38(15_suppl):8509. Abstract.
   Web of Science ®Google Scholar
• Kastritis E, et al. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid. 2020;1–9. DOI:10.1080/13506129.2020.1798224.
   PubMed Web of Science ®Google Scholar
• Bochtler T, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33(12):1371–1378.
   PubMed Web of Science ®Google Scholar
• Bochtler T, et al. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid. 2014;21(1):9–17.
   PubMed Web of Science ®Google Scholar
• Palladini G, et al. Minimal residual disease by next-generation flow cytometry hinders organ response in AL amyloidosis. Blood Cancer J. 2020. In press.
   Web of Science ®Google Scholar
• Palladini G, Merlini G. When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression. Blood Adv. 2019;3(2):212–215.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V. Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details. Blood Adv. 2019;3(2):216–218.
   PubMed Web of Science ®Google Scholar